Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer

Inclusion Criteria: Adults aged 18-75 years, both male and female. Histologically or cytologically confirmed locally advanced unresectable pancreatic cancer. No prior chemotherapy or radiatiotherapy for pancreatic cancer. ECOG performance status of 0-1. Adequate organ function as defined by the following criteria: Absolute neutrophil count (ANC) ≥ 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) Serum creatinine ≤ 1.5 times the ULN AST/ALT ≤ 2.5 times the ULN Ability to provide written informed consent. Exclusion Criteria: Prior history of other malignancies (except for curatively treated non-melanoma skin cancer or other cancers with a 5-year disease-free survival). Active infections or severe medical conditions that would interfere with the study. Pregnancy or breastfeeding. Known hypersensitivity to any of the study drugs. History of severe allergic reactions to liposomal formulations. Uncontrolled comorbid conditions (e.g., heart failure, chronic kidney disease, or uncontrolled diabetes). Participation in other clinical trials involving investigational treatments within 30 days of enrollment.